Chemocentryx, Inc.

Amgen Inc.

Xi Chen

Penglie Zhang

Dean R Dragoli

Hiroko Tanaka

Pingchen Fan

Jay Patrick Powers

Viengkham Malathong

Manmohan Reddy Leleti

Ju Yang

Junfa Fan

Jeffrey P McMahon

Chao Yu

Rajinder Paul Singh

Venkat Reddy Mali

Jaroslaw Kalisiak

Sreenivas Punna

Juan Carlos Jaen

Rebecca M Lui

Yandong Li

Antoni Krasinski

Yibin Zeng

Lianfa Li

Xiaoqi Chen

Jeffrey Thomas Mihalic

Leping Li

Mark M Gleason

Richard V Connors

Mike Elias Lizarzaburu

Kang Dai

Stephen J Shuttleworth

Yong-Jae Kim

Jeffrey P McMAHON

Ying Fu

Oxindole compounds useful for the treatment of CCR(9) mediated conditions or diseases are provided.

2-oxindole compounds

Compounds are provided as inhibitors of CXCR2, having the structure:

Inhibitors of CXCR2

Compounds are provided as chemokine inhibitors having the structure:

Modulators of chemokine receptors

Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are diazole lactam derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.

Diazole lactams

Compounds are provided as inhibitors of CXCR2, having the structure: 

Compounds are provided as chemokine inhibitors having the structure: 

Compounds are provided that act as potent antagonists of the CCR(9) receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR(9). The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR(9)-mediated diseases, and as controls in assays for the identification of CCR(9) antagonists.

Aza-aryl 1H-pyrazol-1-yl benzene sulfonamides

Diazole amides

Growing community of inventors

East Palo Alto, CA, United States of America

Xi Chen